HOME >> BIOLOGY >> NEWS
Cord Blood Registry achieves industry-leading stem cell recovery with new automation technology

San Bruno, CAFebruary 7, 2007Cord Blood Registry (CBR) today announced that it has completed initial validation testing of the company's proprietary CellAdvantageTM system using new automation technology for cell processing, developed by ThermoGenesis and distributed by GE Healthcare. The new technology, called the AXP AutoXpressTM Platform (AXPTM), is the industry's first functionally-closed, automated cord blood stem cell processing technology.

The FDA-required validation testing demonstrated that CBR's CellAdvantage system can meet or exceed the company's current mononuclear cell (MNC) -- or stem cell -- recovery rate of 98 percent, which is the highest published cell recovery rate in the industry. CBR will present data results at an upcoming medical meeting.

"Achieving these extremely high cell recovery rates through automation is a very significant advancement for our company and for the families we serve," said Tom Moore, chief executive officer of CBR. "Our business is experiencing dramatic growth as expectant parents increasingly choose to preserve their baby's cord blood stem cells with us. By integrating AXP automation technology into our CellAdvantage system, CBR is the only family bank that will be able to increase our cell processing capacity and at the same time maintain or exceed our industry-leading cell recovery rates."

Cord Blood Registry is the first and only family cord blood bank to adopt this cutting-edge technology and offer it to consumers who wish to cryopreserve their own genetically-related stem cells for future therapeutic use. The world's largest public donation bank, The New York Blood Center, has also adopted AXP processing.

"In our selection process, we closely evaluated the two automated cell processing systems available on the market, said Moore. "We determined that only AXP can deliver cell recovery rates that can exceed our current cell separation process and do so consistently."


'"/>

Contact: Elissa Armstrong
earmstrong@golinharris.com
312-729-4139
Golin/Harris International
7-Feb-2007


Page: 1 2

Related biology news :

1. Blood test may help signal tumors remission, return in throat cancer patients
2. Blood sugars manufacture limited by building blocks supply
3. Bloods clotting cells harbor ticking time bombs, finding may help extend blood supply
4. Blood tests may be possible for mental health conditions
5. Blood test predicts cardiac events and death in heart patients
6. Blood clot fibers more elastic than spiders web
7. Blood-compatible nanoscale materials possible using heparin
8. Blood pressure medication may revolutionize treatment of Marfan syndrome
9. Blood levels of suspected carcinogen vary by race, ethnicity
10. Blood conservation strategies take center stage at Emory University Hospital forum
11. Blood test for colon cancer risk to be goal of Hopkins project

Post Your Comments:
(Date:5/22/2015)... OXFORD, CT , May 22, 2015  NXT-ID, Inc. ... from June 1st, it will be ending its promotional pricing ... www.wocketwallet.com . Laurence Savin , Head of ... our exclusive promotional pricing until the end of May. To ... at wocketwallet.com/invite and when we open the store on June ...
(Date:5/20/2015)... , May 20, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the addition ... the Global Iris Recognition Market"  report ... , ,This research service analyses trends ... the government and commercial sectors, globally. ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2
(Date:5/26/2015)... May 26, 2015 Tianyin Pharmaceutical Inc. (NYSE ... in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), ... the Company,s Annual Meeting of Shareholders for fiscal year ... held at the Company,s office located in ... 9:00 AM (local time in Chengdu, China ...
(Date:5/26/2015)... 26, 2015 Pharmaco-Kinesis Corporation (PKC) announced today ... at Shutters on the Beach in Santa ... of the Company,s innovative Metronomic Biofeedback Pump (MBP), a ... chemotherapy over time to a target site of the ... biofeedback system in real-time.  ...
(Date:5/26/2015)... May 26, 2015 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral ... the study protocol for the company,s Phase IIb trial ... Food and Drug Administration (FDA). The submission was made ... The Phase IIb study of ORMD-0801 for ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Just the ... a long-standing unmet biomedical need does not guarantee immediate ... problem that has seen many prior failures is often ... acceptance and use is an irony that is often ... small, new start-up company, Asymmetrex has found ...
Breaking Biology Technology:TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 2TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 3In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 2In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 3
Cached News: